Therapeutic compounds

A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula (I):

• wherein,
• R2 is hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• X6 is C—H, C—F, C—Cl, C—Br, or N;
• R5 is hydrogen, halogen, —CN, alkyl, cycloalkyl, or alkoxy;
• R6 is hydrogen, halogen, —CN, alkyl, cycloalkyl, cycloalkylalkyl, —OR22, or —N(R22)2;
• RA is
• R13 is Y—Z;
• Y is selected from a bond, —CH2—, or CH(C1-C4alkyl)-;
• Z is selected from —SO2R21, —N(R22)SO2R21, —SO2N(R22)2, —N(R22)SO2N(R22)2, —CON(R22)2, —N(R22)CO2R21, —N(R22)CON(R22)2, —N(R22)COR21, —COR21, —OC(O)N(R22)2, —OSO2N(R22)2, —OSO2R21, —N(R22)SO3R21, N(R22)2, or —CN;
• X2 is N, or C—R12;
• wherein R12 is hydrogen, halogen, —CN, alkyl, cycloalkyl, or alkoxy;
• X4 is N, or C—R14;
• wherein R14 is hydrogen, halogen, —CN, alkyl, cycloalkyl, or alkoxy;
• X is a bond, —O—, —S—, —N(R7)—, —CH2—, —CF(H)—, —CF2—, or —CH(C1-C5alkyl)-;
• R7 is H or C1-C6 alkyl;
• R1 is alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R21 is independently selected from alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• each R22 is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl;
• and
• provided that the compound of Formula (I) is not N-[2-(2,4-difluorophenoxy)-6-(1,5-dimethyl-6-oxopyridin-3-yl)pyrimidin-4-yl]ethanesulfonamide.